PH12018501132A1 - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents

1,3,4-thiadiazole compounds and their use in treating cancer

Info

Publication number
PH12018501132A1
PH12018501132A1 PH12018501132A PH12018501132A PH12018501132A1 PH 12018501132 A1 PH12018501132 A1 PH 12018501132A1 PH 12018501132 A PH12018501132 A PH 12018501132A PH 12018501132 A PH12018501132 A PH 12018501132A PH 12018501132 A1 PH12018501132 A1 PH 12018501132A1
Authority
PH
Philippines
Prior art keywords
treating cancer
thiadiazole compounds
methylpyridazin
methoxy
hydrogen
Prior art date
Application number
PH12018501132A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Johannes Wilhelmus Maria Nissink
Mark David Charles
James Matthew Wood
Original Assignee
Cancer Research Tech Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd, Astrazeneca Ab filed Critical Cancer Research Tech Ltd
Publication of PH12018501132A1 publication Critical patent/PH12018501132A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PH12018501132A 2015-11-30 2018-05-29 1,3,4-thiadiazole compounds and their use in treating cancer PH12018501132A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30
PCT/EP2016/079251 WO2017093300A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
PH12018501132A1 true PH12018501132A1 (en) 2019-01-21

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018501132A PH12018501132A1 (en) 2015-11-30 2018-05-29 1,3,4-thiadiazole compounds and their use in treating cancer

Country Status (25)

Country Link
US (1) US9938265B2 (enExample)
EP (1) EP3383871B1 (enExample)
JP (1) JP6873132B2 (enExample)
KR (1) KR20180083412A (enExample)
CN (1) CN108349967B (enExample)
AR (1) AR106876A1 (enExample)
AU (1) AU2016363719B2 (enExample)
BR (1) BR112018010812A2 (enExample)
CA (1) CA3005516C (enExample)
CL (1) CL2018001408A1 (enExample)
CO (1) CO2018006929A2 (enExample)
DK (1) DK3383871T3 (enExample)
DO (1) DOP2018000134A (enExample)
EA (1) EA201891240A1 (enExample)
ES (1) ES2759940T3 (enExample)
IL (1) IL258644A (enExample)
MX (1) MX2018006528A (enExample)
NI (1) NI201800065A (enExample)
PE (1) PE20181450A1 (enExample)
PH (1) PH12018501132A1 (enExample)
SG (1) SG11201803813UA (enExample)
SV (1) SV2018005701A (enExample)
TN (1) TN2018000126A1 (enExample)
TW (1) TW201730188A (enExample)
WO (1) WO2017093300A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201733587A (zh) * 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
WO2020078350A1 (zh) * 2018-10-16 2020-04-23 南京明德新药研发有限公司 噻二唑衍生物及其作为gls1抑制剂的应用
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003514910A (ja) * 1999-11-24 2003-04-22 メルク エンド カムパニー インコーポレーテッド Hivプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−2−(フルオロアルキルアミノカルボニル)−1−ピペラジンペンタンアミド類
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
EP1828144A2 (en) * 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
CA2758210C (en) * 2009-04-20 2017-08-29 F. Hoffmann-La Roche Ag Proline derivatives as cathepsin inhibitors
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
ES2899461T3 (es) * 2012-11-16 2022-03-11 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CN111892589A (zh) * 2014-01-06 2020-11-06 理森制药股份公司 谷氨酰胺酶抑制剂
EP3116872A4 (en) * 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
BR112018010812A2 (pt) 2018-11-27
ES2759940T3 (es) 2020-05-12
IL258644A (en) 2018-06-28
SV2018005701A (es) 2018-11-27
JP2019501134A (ja) 2019-01-17
EA201891240A1 (ru) 2018-11-30
SG11201803813UA (en) 2018-06-28
DK3383871T3 (da) 2019-12-16
CN108349967A (zh) 2018-07-31
CA3005516C (en) 2024-04-16
MX2018006528A (es) 2019-05-15
NI201800065A (es) 2018-10-18
CL2018001408A1 (es) 2018-10-12
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
KR20180083412A (ko) 2018-07-20
ES2759940T8 (es) 2020-05-20
CA3005516A1 (en) 2017-06-08
EP3383871A1 (en) 2018-10-10
AU2016363719A8 (en) 2018-07-12
AU2016363719A1 (en) 2018-07-05
CN108349967B (zh) 2022-02-15
EP3383871B1 (en) 2019-09-11
CO2018006929A2 (es) 2018-10-10
TN2018000126A1 (en) 2019-10-04
DOP2018000134A (es) 2018-06-30
PE20181450A1 (es) 2018-09-12
AR106876A1 (es) 2018-02-28
TW201730188A (zh) 2017-09-01
AU2016363719B2 (en) 2019-11-14
US20170152254A1 (en) 2017-06-01
JP6873132B2 (ja) 2021-05-19

Similar Documents

Publication Publication Date Title
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
PH12019501919A1 (en) Dioxolane analogues of uridine for the treatment of cancer
PH12018501132A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MX392829B (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
GEP20197043B (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
MY189557A (en) Pyridone compound as c-met inhibitor
PH12018501131A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2018001317A (es) Inhibidores del virus sincitial respiratorio.
MX2018006374A (es) Compuestos de bis-piridazina y su uso en el tratamiento del cancer.
PH12017500492A1 (en) Crystalline bace inhibitors
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
MY196907A (en) Phenylimidazole compound
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.